

Media
Press releases
23May
Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
13May
Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation
21Apr
Regulatory press release
Hansa Biopharma interim report January – March 2022
Media assets
Executive Leadership Team

Dr Christian Kjellman
Senior Vice President, Chief Scientific Officer, Research and Development